New combo therapy tested for Tough-to-Treat breast cancer
NCT ID NCT05064085
Summary
This early-stage study is testing the safety of combining two drugs—an oral chemotherapy called capecitabine and an immunotherapy called cemiplimab—for people with advanced hormone-positive breast cancer that has spread. The main goal is to find the safest dose to use in future studies. Researchers will also check if the treatment helps shrink tumors or slow the cancer's growth.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HORMONE RECEPTOR-POSITIVE BREAST CANCER are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Moffitt Cancer Center
Tampa, Florida, 33612, United States
Conditions
Explore the condition pages connected to this study.